Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors
- 27 May 2019
- journal article
- research article
- Published by Springer Nature in Heart Failure Reviews
- Vol. 24 (6) , 977-987
Abstract
The number of breast cancer (BC) survivors has been increasing lately, due to the improvement in early detection strategies and oncological treatments. However, BC survivors are 3 times as likely to develop heart failure (HF) within 5 years of cancer diagnosis, and 7/100 of them will develop HF in a median follow-up of 8.5 years. Furthermore, HF in BC survivors has a worse prognosis compared to other causes of HF. Anthracyclines and trastuzumab have been proven to improve survival. However, they are also considered as the main causative factors of HF in BC survivors. Old patients, those with a pre-existing cardiovascular (CV) risk factors/disease, prior exposure to chemotherapy and radiotherapy are at increased risk. Serial evaluation of troponins and cardiac imaging parameters using echocardiography and cardiovascular magnetic resonance can significantly contribute to the early diagnosis of cardiac involvement before overt HF will develop. Assessment and immediate treatment of traditional CV risk factors is the first step for cardiotoxicity prevention. In BC survivors with known heart disease, the clinical stabilization is strongly recommended for cardiotoxicity prevention. Finally, in high-risk CV patients, primary prevention including cardioprotectants and/or CV drugs should be applied. According to recent studies, the early start of ACE inhibitors and β-blockers and the modification of anti-cancer treatment can prevent the decline in left ventricular ejection fraction. However, further multicenter studies are needed to establish both prevention and treatment protocols to successfully overcome HF development in BC survivors.Keywords
This publication has 81 references indexed in Scilit:
- Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control studyInternational Journal of Cardiology, 2013
- Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 2013
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2012
- Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I EvaluationJournal of Clinical Oncology, 2010
- The utility of troponin measurement to detect myocardial infarction: review of the current findingsVascular Health and Risk Management, 2010
- Anthracycline-Induced CardiomyopathyJACC, 2010
- Doxorubicin CardiomyopathyCardiology, 2009
- Cardiovascular magnetic resonance in pericardial diseasesJournal of Cardiovascular Magnetic Resonance, 2009
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004